{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:53:40Z","timestamp":1790409220926,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_162552 \/ 1"],"award-info":[{"award-number":["310030_162552 \/ 1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KE 1831\/1-1"],"award-info":[{"award-number":["KE 1831\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12974-016-0506-x","type":"journal-article","created":{"date-parts":[[2016,2,18]],"date-time":"2016-02-18T15:06:20Z","timestamp":1455807980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation"],"prefix":"10.1186","volume":"13","author":[{"given":"Isaak","family":"Quast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Gunten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,18]]},"reference":[{"key":"506_CR1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD Lunemann","year":"2015","unstructured":"Lunemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy. Nat Rev Neurol. 2015;11:80\u20139.","journal-title":"Nat Rev Neurol"},{"key":"506_CR2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1172\/JCI117012","volume":"93","author":"A Achiron","year":"1994","unstructured":"Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, et al. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest. 1994;93:600\u20135.","journal-title":"J Clin Invest"},{"key":"506_CR3","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/eji.201444440","volume":"44","author":"S Othy","year":"2014","unstructured":"Othy S, Topcu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Kasermann F, et al. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur J Immunol. 2014;44:2059\u201363.","journal-title":"Eur J Immunol"},{"key":"506_CR4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2012-11-468264","volume":"122","author":"J Trinath","year":"2013","unstructured":"Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood. 2013;122:1419\u201327.","journal-title":"Blood"},{"key":"506_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2005.03.005","volume":"233","author":"S Humle Jorgensen","year":"2005","unstructured":"Humle Jorgensen S, Sorensen PS. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci. 2005;233:61\u20135.","journal-title":"J Neurol Sci"},{"key":"506_CR6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00221-006-0752-8","volume":"178","author":"SH Jorgensen","year":"2007","unstructured":"Jorgensen SH, Storm N, Jensen PE, Laursen H, Sorensen PS. IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp Brain Res. 2007;178:462\u20139.","journal-title":"Exp Brain Res"},{"key":"506_CR7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","volume":"111","author":"A Ephrem","year":"2008","unstructured":"Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4\u2009+\u2009CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715\u201322.","journal-title":"Blood"},{"key":"506_CR8","doi-asserted-by":"crossref","first-page":"E2385","DOI":"10.1073\/pnas.1505292112","volume":"112","author":"BM Fiebiger","year":"2015","unstructured":"Fiebiger BM, Maamary J, Pincetic A, Ravetch JV. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci U S A. 2015;112:E2385\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"506_CR9","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","volume":"63","author":"PS Sorensen","year":"2004","unstructured":"Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M, Group TS. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63:2028\u201333.","journal-title":"Neurology"},{"key":"506_CR10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","volume":"10","author":"LH Visser","year":"2004","unstructured":"Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler. 2004;10:89\u201391.","journal-title":"Mult Scler"},{"key":"506_CR11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","volume":"364","author":"OR Hommes","year":"2004","unstructured":"Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004;364:1149\u201356.","journal-title":"Lancet"},{"key":"506_CR12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","volume":"71","author":"F Fazekas","year":"2008","unstructured":"Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008;71:265\u201371.","journal-title":"Neurology"},{"key":"506_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","volume":"13","author":"JD L\u00fcnemann","year":"2016","unstructured":"L\u00fcnemann JD, Quast I, Dalakas MC. Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics. 2016;13:34\u201346.","journal-title":"Neurotherapeutics."},{"key":"506_CR14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","volume":"3","author":"R Gold","year":"2007","unstructured":"Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology\u2014therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3:36\u201344.","journal-title":"Nat Clin Pract Neurol"},{"key":"506_CR15","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","volume":"105","author":"RM Anthony","year":"2008","unstructured":"Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008;105:19571\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"506_CR16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","volume":"18","author":"P Bruhns","year":"2003","unstructured":"Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 2003;18:573\u201381.","journal-title":"Immunity"},{"key":"506_CR17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20051900","volume":"203","author":"Y Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med. 2006;203:789\u201397.","journal-title":"J Exp Med"},{"key":"506_CR18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","volume":"313","author":"Y Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670\u20133.","journal-title":"Science"},{"key":"506_CR19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484\u20136.","journal-title":"Science"},{"key":"506_CR20","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","volume":"21","author":"U Pawel-Rammingen von","year":"2002","unstructured":"von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002;21:1607\u201315.","journal-title":"EMBO J"},{"key":"506_CR21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1084\/jem.20021603","volume":"197","author":"E Bettelli","year":"2003","unstructured":"Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197:1073\u201381.","journal-title":"J Exp Med"},{"key":"506_CR22","first-page":"Unit 15 11","volume":"Chapter 15","author":"SD Miller","year":"2007","unstructured":"Miller SD, Karpus WJ. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol. 2007;Chapter 15:Unit 15 11.","journal-title":"Curr Protoc Immunol"},{"key":"506_CR23","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.4049\/jimmunol.181.8.5748","volume":"181","author":"F Frommer","year":"2008","unstructured":"Frommer F, Heinen TJ, Wunderlich FT, Yogev N, Buch T, Roers A, et al. Tolerance without clonal expansion: self-antigen-expressing B cells program self-reactive T cells for future deletion. J Immunol. 2008;181:5748\u201359.","journal-title":"J Immunol"},{"key":"506_CR24","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/nprot.2006.284","volume":"1","author":"IM Stromnes","year":"2006","unstructured":"Stromnes IM, Goverman JM. Passive induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1:1952\u201360.","journal-title":"Nat Protoc"},{"key":"506_CR25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ni.2027","volume":"12","author":"L Codarri","year":"2011","unstructured":"Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011;12:560\u20137.","journal-title":"Nat Immunol"},{"key":"506_CR26","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1182\/blood-2010-11-322206","volume":"117","author":"B Geering","year":"2011","unstructured":"Geering B, Gurzeler U, Federzoni E, Kaufmann T, Simon HU. A novel TNFR1-triggered apoptosis pathway mediated by class IA PI3Ks in neutrophils. Blood. 2011;117:5953\u201362.","journal-title":"Blood"},{"key":"506_CR27","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.4049\/jimmunol.1400028","volume":"193","author":"M Wehrli","year":"2014","unstructured":"Wehrli M, Cortinas-Elizondo F, Hlushchuk R, Daudel F, Villiger PM, Miescher S, et al. Human IgA Fc receptor FcalphaRI (CD89) triggers different forms of neutrophil death depending on the inflammatory microenvironment. J Immunol. 2014;193:5649\u201359.","journal-title":"J Immunol"},{"key":"506_CR28","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","volume":"108","author":"S Gunten von","year":"2006","unstructured":"von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood. 2006;108:4255\u20139.","journal-title":"Blood"},{"key":"506_CR29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.immuni.2015.08.010","volume":"43","author":"AL Croxford","year":"2015","unstructured":"Croxford AL, Lanzinger M, Hartmann FJ, Schreiner B, Mair F, Pelczar P, et al. The cytokine GM-CSF drives the inflammatory signature of CCR2(+) monocytes and licenses autoimmunity. Immunity. 2015;43:502\u201314.","journal-title":"Immunity"},{"key":"506_CR30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1189\/jlb.70.6.849","volume":"70","author":"A Billiau","year":"2001","unstructured":"Billiau A, Matthys P. Modes of action of Freund\u2019s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001;70:849\u201360.","journal-title":"J Leukoc Biol"},{"key":"506_CR31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340.","journal-title":"J Exp Med"},{"key":"506_CR32","first-page":"763","volume":"147","author":"H Lassmann","year":"1991","unstructured":"Lassmann H, Zimprich F, Rossler K, Vass K. Inflammation in the nervous system. Basic mechanisms and immunological concepts. Rev Neurol (Paris). 1991;147:763\u201381.","journal-title":"Rev Neurol (Paris)"},{"key":"506_CR33","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.1202613","volume":"191","author":"K Steinbach","year":"2013","unstructured":"Steinbach K, Piedavent M, Bauer S, Neumann JT, Friese MA. Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs. J Immunol. 2013;191:4531\u20139.","journal-title":"J Immunol"},{"key":"506_CR34","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2003.09.045","volume":"112","author":"F Altznauer","year":"2003","unstructured":"Altznauer F, von Gunten S, Spath P, Simon HU. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol. 2003;112:1185\u201390.","journal-title":"J Allergy Clin Immunol"},{"key":"506_CR35","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood-2004-10-4112","volume":"106","author":"S Gunten von","year":"2005","unstructured":"von Gunten S, Yousefi S, Seitz M, Jakob SM, Schaffner T, Seger R, et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood. 2005;106:1423\u201331.","journal-title":"Blood"},{"key":"506_CR36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/sur.2012.227","volume":"15","author":"M Aoyama-Ishikawa","year":"2014","unstructured":"Aoyama-Ishikawa M, Seishu A, Kawakami S, Maeshige N, Miyoshi M, Ueda T, et al. Intravenous immunoglobulin-induced neutrophil apoptosis in the lung during murine endotoxemia. Surg Infect (Larchmt). 2014;15:36\u201342.","journal-title":"Surg Infect (Larchmt)"},{"key":"506_CR37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0731-7085(00)00297-1","volume":"22","author":"F Lamari","year":"2000","unstructured":"Lamari F, Karamanos NK, Papadopoulou-Alataki E, Kanakoudi-Tsakalidou F, Dimitracopoulos G, Anastassiou ED. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients. J Pharm Biomed Anal. 2000;22:1029\u201336.","journal-title":"J Pharm Biomed Anal"},{"key":"506_CR38","doi-asserted-by":"crossref","first-page":"269ra261","DOI":"10.1126\/scitranslmed.3010524","volume":"7","author":"C Schneider","year":"2015","unstructured":"Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, et al. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med. 2015;7:269ra261.","journal-title":"Sci Transl Med"},{"key":"506_CR39","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1128\/IAI.73.9.6101-6109.2005","volume":"73","author":"E Roy","year":"2005","unstructured":"Roy E, Stavropoulos E, Brennan J, Coade S, Grigorieva E, Walker B, et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun. 2005;73:6101\u20139.","journal-title":"Infect Immun"},{"key":"506_CR40","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.178.4.2589","volume":"178","author":"P Thakker","year":"2007","unstructured":"Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol. 2007;178:2589\u201398.","journal-title":"J Immunol"},{"key":"506_CR41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1179\/016164105X48798","volume":"27","author":"SH Jorgensen","year":"2005","unstructured":"Jorgensen SH, Jensen PE, Laursen H, Sorensen PS. Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurol Res. 2005;27:591\u20137.","journal-title":"Neurol Res"},{"key":"506_CR42","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.4049\/jimmunol.139.12.4016","volume":"139","author":"HJ Schluesener","year":"1987","unstructured":"Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol. 1987;139:4016\u201321.","journal-title":"J Immunol"},{"key":"506_CR43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1212\/WNL.43.5.857","volume":"43","author":"TP Bleck","year":"1993","unstructured":"Bleck TP. IVIg for GBS: potential problems in the alphabet soup. Neurology. 1993;43:857\u20138.","journal-title":"Neurology"},{"key":"506_CR44","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/WNL.43.5.1034","volume":"43","author":"LH Castro","year":"1993","unstructured":"Castro LH, Ropper AH. Human immune globulin infusion in Guillain-Barre syndrome: worsening during and after treatment. Neurology. 1993;43:1034\u20136.","journal-title":"Neurology"},{"key":"506_CR45","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.43.5.872","volume":"43","author":"DN Irani","year":"1993","unstructured":"Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barre syndrome after treatment with human immune globulin. Neurology. 1993;43:872\u20135.","journal-title":"Neurology"},{"key":"506_CR46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.intimp.2005.11.003","volume":"6","author":"EW Gelfand","year":"2006","unstructured":"Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6:592\u20139.","journal-title":"Int Immunopharmacol"},{"issue":"Suppl","key":"506_CR47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/jnnp.57.Suppl.57","volume":"57","author":"A Achiron","year":"1994","unstructured":"Achiron A, Gilad R, Margalit R, Gabbay U, Sarova-Pinhas I, Cohen IR, et al. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry. 1994;57(Suppl):57\u201361.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"506_CR48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(01)00243-0","volume":"114","author":"O Aktas","year":"2001","unstructured":"Aktas O, Waiczies S, Grieger U, Wendling U, Zschenderlein R, Zipp F. Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. J Neuroimmunol. 2001;114:160\u20137.","journal-title":"J Neuroimmunol"},{"key":"506_CR49","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","volume":"161","author":"NK Prasad","year":"1998","unstructured":"Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161:3781\u201390.","journal-title":"J Immunol"},{"key":"506_CR50","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<1823::AID-IMMU1823>3.0.CO;2-F","volume":"28","author":"A Pashov","year":"1998","unstructured":"Pashov A, Dubey C, Kaveri SV, Lectard B, Huang YM, Kazatchkine MD, et al. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol. 1998;28:1823\u201331.","journal-title":"Eur J Immunol"},{"key":"506_CR51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00401-002-0568-y","volume":"104","author":"A Weishaupt","year":"2002","unstructured":"Weishaupt A, Kuhlmann T, Schonrock LM, Toyka KV, Bruck W, Gold R. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol. 2002;104:385\u201390.","journal-title":"Acta Neuropathol"},{"key":"506_CR52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176\u201389.","journal-title":"Nat Rev Immunol"},{"key":"506_CR53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"RM Anthony","year":"2008","unstructured":"Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320:373\u20136.","journal-title":"Science"},{"key":"506_CR54","doi-asserted-by":"crossref","first-page":"E1297","DOI":"10.1073\/pnas.1422481112","volume":"112","author":"N Washburn","year":"2015","unstructured":"Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A. 2015;112:E1297\u2013306.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"506_CR55","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.4049\/jimmunol.180.3.1948","volume":"180","author":"L Baudino","year":"2008","unstructured":"Baudino L, Nimmerjahn F, Azeredo da Silveira S, Martinez-Soria E, Saito T, Carroll M, et al. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol. 2008;180:1948\u201353.","journal-title":"J Immunol"},{"key":"506_CR56","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","volume":"115","author":"SA Beers","year":"2010","unstructured":"Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191\u2013201.","journal-title":"Blood"},{"key":"506_CR57","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.immuni.2011.11.009","volume":"35","author":"M Biburger","year":"2011","unstructured":"Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity. 2011;35:932\u201344.","journal-title":"Immunity"},{"key":"506_CR58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/1074-7613(95)90155-8","volume":"3","author":"R Clynes","year":"1995","unstructured":"Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3:21\u20136.","journal-title":"Immunity"},{"key":"506_CR59","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1084\/jem.191.8.1293","volume":"191","author":"L Fossati-Jimack","year":"2000","unstructured":"Fossati-Jimack L, Ioan-Facsinay A, Reininger L, Chicheportiche Y, Watanabe N, Saito T, et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J Exp Med. 2000;191:1293\u2013302.","journal-title":"J Exp Med"},{"key":"506_CR60","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1084\/jem.20052283","volume":"203","author":"Y Hamaguchi","year":"2006","unstructured":"Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203:743\u201353.","journal-title":"J Exp Med"},{"key":"506_CR61","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0952-7915(02)00409-0","volume":"14","author":"PM Hogarth","year":"2002","unstructured":"Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol. 2002;14:798\u2013802.","journal-title":"Curr Opin Immunol"},{"key":"506_CR62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.immuni.2005.05.010","volume":"23","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005;23:41\u201351.","journal-title":"Immunity"},{"key":"506_CR63","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","volume":"310","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310:1510\u20132.","journal-title":"Science"},{"key":"506_CR64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.immunol.16.1.421","volume":"16","author":"JV Ravetch","year":"1998","unstructured":"Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol. 1998;16:421\u201332.","journal-title":"Annu Rev Immunol"},{"key":"506_CR65","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1084\/jem.184.6.2385","volume":"184","author":"D Sylvestre","year":"1996","unstructured":"Sylvestre D, Clynes R, Ma M, Warren H, Carroll MC, Ravetch JV. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med. 1996;184:2385\u201392.","journal-title":"J Exp Med"},{"key":"506_CR66","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1126\/science.8066448","volume":"265","author":"DL Sylvestre","year":"1994","unstructured":"Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science. 1994;265:1095\u20138.","journal-title":"Science"},{"key":"506_CR67","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0092-8674(94)90115-5","volume":"76","author":"T Takai","year":"1994","unstructured":"Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76:519\u201329.","journal-title":"Cell"},{"key":"506_CR68","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","volume":"199","author":"J Uchida","year":"2004","unstructured":"Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659\u201369.","journal-title":"J Exp Med"},{"key":"506_CR69","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.161.9.4480","volume":"161","author":"P Hjelmstrom","year":"1998","unstructured":"Hjelmstrom P, Juedes AE, Fjell J, Ruddle NH. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol. 1998;161:4480\u20133.","journal-title":"J Immunol"},{"key":"506_CR70","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.184.6.2271","volume":"184","author":"SD Wolf","year":"1996","unstructured":"Wolf SD, Dittel BN, Hardardottir F, Janeway Jr CA. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med. 1996;184:2271\u20138.","journal-title":"J Exp Med"},{"key":"506_CR71","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D","volume":"28","author":"HP Eugster","year":"1998","unstructured":"Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol. 1998;28:2178\u201387.","journal-title":"Eur J Immunol"},{"key":"506_CR72","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1073\/pnas.252777399","volume":"100","author":"R Pedotti","year":"2003","unstructured":"Pedotti R, DeVoss JJ, Youssef S, Mitchell D, Wedemeyer J, Madanat R, et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci U S A. 2003;100:1867\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"506_CR73","doi-asserted-by":"crossref","first-page":"18697","DOI":"10.1073\/pnas.0607283103","volume":"103","author":"E Urich","year":"2006","unstructured":"Urich E, Gutcher I, Prinz M, Becher B. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc Natl Acad Sci U S A. 2006;103:18697\u2013702.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"506_CR74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490\u20133.","journal-title":"Science"},{"key":"506_CR75","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00006454-199906000-00006","volume":"18","author":"JB Bruss","year":"1999","unstructured":"Bruss JB, Malley R, Halperin S, Dobson S, Dhalla M, McIver J, et al. Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr Infect Dis J. 1999;18:505\u201311.","journal-title":"Pediatr Infect Dis J"},{"key":"506_CR76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biologicals.2012.10.003","volume":"41","author":"CY Wu","year":"2013","unstructured":"Wu CY, Wang HC, Wang KT, Yang-Chih Shih D, Lo CF, Wang DY. Analyzing titers of antibodies against bacterial and viral antigens, and bacterial toxoids in the intravenous immunoglobulins utilized in Taiwan. Biologicals. 2013;41:88\u201392.","journal-title":"Biologicals"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-016-0506-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T12:32:28Z","timestamp":1718368348000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jneuroinflammation.com\/content\/13\/1\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,18]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s12974-016-0506-x","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,18]]},"article-number":"42"}}